nach oben

Erschienen in:

01.06.2003 | Originalien

Spezifische Immuntherapien zur Behandlung von Krebs im Kindesalter

verfasst von: C. Rössig, D. Dilloo, H. Jürgens

Erschienen in: Monatsschrift Kinderheilkunde | Ausgabe 6/2003

Einloggen, um Zugang zu erhalten

Zusammenfassung

Immuntherapie.

Die Immuntherapie bösartiger Tumoren beruht auf dem Konzept, durch gezielte Verstärkung tumorspezifischer Immunantworten eine Abstoßung der Tumorzellen herbeizuführen. Dazu kann entweder durch aktive Immunisierung eine tumorspezifische Aktivierung des Immunsystems induziert oder es können Effektoren des Immunsystems, wie Antikörper oder ex vivo expandierte zytotoxische T-Zellen, passiv verabreicht werden.

Einsatz in der Pädiatrie.

Der gezielte Einsatz immunologischer Therapiemodalitäten könnte eine sinnvolle Ergänzung zur Standardtherapie vieler pädiatrischer Tumoren darstellen. In dieser Übersicht werden aktuelle Konzepte zu den Mechanismen der Antitumorimmunität und ihrer Beeinflussung durch therapeutische Maßnahmen vorgestellt und der Stellenwert der Immuntherapie in der pädiatrischen Onkologie diskutiert.

Atra A, Millar B, Shepherd V, Shankar A, Wilson K, Treleaven J, Pritchard-Jones K, Meller ST, Pinkerton CR (1997) Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation. Br J Haematol 97: 165–168PubMedCrossRef

Berthold F (1998) Studienleiter. Kooperative multizentrische Therapieoptimierungsstudie für die Behandlung von Säuglingen, Kindern und Jugendlichen mit Neuroblastom (NB 97). Universitätskinderklinik Köln

Bowman LC, Grossmann M, Rill D, Brown M, Zhong WY, Alexander B, Leimig T, Coustan-Smith E, Campana D, Jenkins J, Woods D, Brenner M (1998) Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 9: 1303–1311PubMedCrossRef

Bowman L, Grossmann M, Rill D, Brown M, Zhong WY, Alexander B, Leimig T, Coustan-Smith E, Campana D, Jenkins J, Woods D, Kitchingman G, Vanin E, Brenner M (1998) IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 92: 1941–1949PubMedCrossRef

Cai X, Garen A (1995) Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc Natl Acad Sci USA 92: 6537–6541PubMedPubMedCentralCrossRef

Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, Rojas J, Bourdon A, Bonner PL, Wang L, Christmas SE, Travers PJ, Creaser CS, Rees RC, Madrigal JA (2001) Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98: 2887–2893PubMedCrossRef

Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15: 433–444PubMedCrossRef

Couderc B, Zitvogel L, Douin-Echinard V, Djennane L, Tahara H, Favre G, Lotze MT, Robbins PD (1998) Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther 5: 163–175PubMed

Dilloo D, Bacon K, Holden W, Zhong W, Burdach S, Zlotnik A, Brenner M (1996) Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 2: 1090–1095PubMedCrossRef

10.

Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539–3543PubMedPubMedCentralCrossRef

11.

Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90: 720–724PubMedPubMedCentralCrossRef

12.

Faye A, Van Den AT, Peuchmaur M, Mathieu-Boue A, Vilmer E (1998) Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 352: 1285PubMedCrossRef

13.

Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397–403PubMedCrossRef

14.

Frost JD, Hank, JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM (1997) A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 80: 317–333PubMedCrossRef

15.

Gahn B, Siller-Lopez F, Pirooz AD, Yvon E, Gottschalk S, Longnecker R, Brenner MK, Heslop HE, Aguilar-Cordova E, Rooney CM (2001) Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2 A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer 93: 706–713PubMedCrossRef

16.

Gattenloehner S, Vincent A, Leuschner I, Tzartos S, Muller-Hermelink HK, Kirchner T, Marx A (1998) The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors. Am J Pathol 152: 437–444PubMedPubMedCentral

17.

Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ (2001) Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61: 8513–8519PubMed

18.

Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, Meyers PA (1999) Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17: 2781–2788PubMedCrossRef

19.

Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM (1994) Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84: 3261–3282PubMedCrossRef

20.

Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, Reuland P, Gillies SD, Reisfeld RA, Niethammer D (1995) A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 31A: 261–267PubMedCrossRef

21.

Hasholzner U, Stieber P, Meier W, Lamerz R (1997) Value of HAMA-determination in clinical practice – an overview. Anticancer Res 17: 3055–3058PubMed

22.

Henderson RA, Finn OJ (1996) Human tumor antigens are ready to fly. Adv Immunol 62: 217–256PubMedCrossRef

23.

Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2: 551–555PubMedCrossRef

24.

Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52–58PubMedCrossRef

25.

Ishida H, Matsumura T, Salgaller ML, Ohmizono Y, Kadono Y, Sawada T (1996) MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer 69: 375–380PubMedCrossRef

26.

Kaatsch P, Spix C, Michaelis J (Hrsg) (2000) Jahresbericht 1999. Deutsches Kinderkrebsregister, Mainz

27.

Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab M, Antonescu CR, Peterson C, Meltzer PS (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7: 673–679PubMedPubMedCentralCrossRef

28.

Khazaeli MB, Conry RM, LoBuglio AF (1994) Human immune response to monoclonal antibodies. J Immunother 15: 42–52CrossRef

29.

Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86: 2041–2050

30.

Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, Rooney CM, Heslop HE (2000) CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 95: 1502–1505PubMedCrossRef

31.

Kushner BH, Kramer K, Cheung NK (2001) Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 19: 4189–4194PubMedCrossRef

32.

Leda M, Ladon D, Pieczonka A, Boruczkowski D, Jolkowska J, Witt M, Wachowiak J (2001) Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk Res 25: 353–357PubMedCrossRef

33.

Lima M de, Bonamino M, Vasconcelos Z, Colares M, Diamond H, Zalcberg I, Tavares R, Lerner D, Byington R, Bouzas L, Matta J da, Andrade C, Carvalho L, Pires V, Barone B, Maciel C, Tabak D (2001) Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant 27: 73–78PubMedCrossRef

34.

Lode HN, Xiang R, Duncan SR, Theofilopoulos AN, Gillies SD, Reisfeld RA (1999) Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci USA 96: 8591–8596PubMedPubMedCentralCrossRef

35.

Mackall CL, Bare CV, Granger LA, Sharrow SO, Titus JA, Gress RE (1996) Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 156: 4609–4616PubMedCrossRef

36.

Mackall C, Berzofsky J, Helman LJ (2000) Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. Clin Orthop 25–31

37.

Maitra A, Wanzer D, Weinberg AG, Ashfaq R (2001) Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 92: 677–683PubMedCrossRef

38.

Maloney DG (2001) Mechanism of action of rituximab. Anticancer Drugs [Suppl 2] 12: S1–S4

39.

Manzke O, Berthold F, Huebel K, Tesch H, Diehl V, Bohlen H (1999) CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow. Int J Cancer 80: 715–722PubMedCrossRef

40.

McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825–2833PubMedCrossRef

41.

Merino ME, Navid F, Christensen BL, Toretsky JA, Helman LJ, Cheung NK, Mackall CL (2001) Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction. J Clin Oncol 19: 3649–3659PubMedCrossRef

42.

Miller RA, Maloney DG, Warnke R, Levy R (1982) Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306: 517–522PubMedCrossRef

43.

Mocellin S, Wang E, Marincola FM (2001) Cytokines and immune response in the tumor microenvironment. J Immunother 24: 392–407PubMedCrossRef

44.

Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK (1999) A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5: 1331–1338PubMed

45.

Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E (1999) Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 93: 2336–2341PubMedCrossRef

46.

Nauts HC (1989) Bacteria and cancer-antagonisms and benefits. Cancer Surv 8: 713–723PubMed

47.

Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with pep. Nat Med 4: 328–332PubMedCrossRef

48.

Ollert MW, David K, Schmitt C, Hauenschild A, Bredehorst R, Erttmann R, Vogel CW (1996) Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc Natl Acad Sci USA 93: 4498–4503PubMedPubMedCentralCrossRef

49.

Onda M, Matsuda S, Higaki S, Iijima T, Fukushima J, Yokokura A, Kojima T, Horiuchi H, Kurokawa T, Yamamoto T (1996) ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77: 71–78PubMedCrossRef

50.

Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, Matthay KK, Reaman GH, Seeger RC (2000) Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 18: 4077–4085PubMedCrossRef

51.

Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345: 9–13PubMedCrossRef

52.

Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318–1321PubMedCrossRef

53.

Rossig C, Nuchtern JG, Brenner MK (2000) Selection of human antitumor single-chain Fv antibodies from the B-cell repertoire of patients immunized against autologous neuroblastoma. Med Pediatr Oncol 35: 692–695PubMedCrossRef

54.

Rossig C, Bollard CM, Nuchtern JG, Merchant DA, Brenner MK (2001) Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 15: 228–236CrossRef

55.

Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russell CH (1992) Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 52: 4342–4347PubMed

56.

Sarkar AK, Nuchtern JG (2000) Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res 60: 1908–1913PubMed

57.

Schmitt C, David K, Hiller J, Schrum J, Bredehorst R, Vogel CW, Loliger C, Erttmann R (1999) [Natural human IgM-antibodies in neuroblastoma therapy: preliminary findings of a phase I/II clinical trial]. Klin Pädiatr 211: 314–318PubMedCrossRef

58.

Seo N, Hayakawa S, Takigawa M, Tokura Y (2001) Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 103: 449–457PubMedPubMedCentralCrossRef

59.

Shibuya A, Ishii S, Sasaki N (2001) Successful donor lymphocyte infusion in a patient with relapse of lymphoblastic leukemia after bone marrow transplantation. Pediatr Int 43: 169–171PubMedCrossRef

60.

Sievers EL (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther 1: 893–901PubMedCrossRef

61.

Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R (1995) Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 23: 1553–1562PubMed

62.

Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS (1997) Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 186: 645–653PubMedPubMedCentralCrossRef

63.

Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy G (1996) Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 28: 65–69PubMedCrossRef

64.

Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, Murphy GP (1999) Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40: 125–129PubMedCrossRef

65.

Warren EH, Greenberg PD, Riddell SR (1998) Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 91: 2197–2207PubMedCrossRef

66.

Wu RS, Kobie JJ, Besselsen DG, Fong TC, Mack VD, McEarchern JA, Akporiaye ET (2001) Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol Immunother 50: 229–240PubMedCrossRef

67.

Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA, Kung FH (1998) Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 16: 2169–2180PubMedCrossRef

Titel: Spezifische Immuntherapien zur Behandlung von Krebs im Kindesalter
verfasst von: C. Rössig
D. Dilloo
H. Jürgens
Publikationsdatum: 01.06.2003
Verlag: Springer Berlin Heidelberg
Erschienen in: Monatsschrift Kinderheilkunde / Ausgabe 6/2003
Print ISSN: 0026-9298
Elektronische ISSN: 1433-0474
DOI: https://doi.org/10.1007/s00112-002-0530-z

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Spezifische Immuntherapien zur Behandlung von Krebs im Kindesalter

Zusammenfassung

Immuntherapie.

Einsatz in der Pädiatrie.

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie

Springer Medizin

Zusammenfassung

Immuntherapie.

Einsatz in der Pädiatrie.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2003

Interaktion zwischen Kleinkindern und ihren Vätern

Ichthyosis, spastische Diplegie und mentale Retardierung

Frühe Elternschaft: jugendliche Mütter und ihre Kinder

Effektivität der ketogenen Diät bei therapierefraktären Epilepsien

Akute Alkoholintoxikationen bei Kindern und Jugendlichen

Geschlechtsspezifische Bewältigung bei jungen Menschen mit Körperbehinderungen

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie